An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma.

Trial Profile

An Open Label, Non Comparative, Phase III Study of the Raf Kinase Inhibitor BAY 43-9006 as a Subsequent to First Line Therapy in Patients With Advanced Renal Cell Carcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jan 2015

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Sponsors Bayer
  • Most Recent Events

    • 21 Nov 2012 New source identified and integrated (German Clinical Trials Register, DRKS00004072).
    • 09 Jun 2009 Actual end date changed from Oct 2008 to Nov 2008 as reported by ClinicalTrials.gov.
    • 30 Nov 2008 Status changed from active, no longer recruiting to completed, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top